IPO of Sopan Pharmaceuticals for Public from Baishakh 3
Sopan Pharmaceuticals has launched its IPO, offering over 3.47 million shares to the general public with applications open until Baishakh 8.
Sopan Pharmaceuticals Limited has officially opened its Initial Public Offering (IPO) to the general public from Baishakh 3, 2083.
The company is issuing 3,474,900 shares at a face value of Rs. 100 per unit. The IPO is scheduled to close on Baishakh 8, with a provision to extend the deadline until Baishakh 17 if it remains undersubscribed.
Out of the company’s total issued capital of Rs. 1.71 billion, 25%—equivalent to 4,290,000 shares—has been allocated to the public. From this portion, 10% (429,000 shares) has already been allotted to Nepali workers abroad. Similarly, 4% (171,600 shares) has been reserved for employees, and 5% (214,500 shares) for mutual funds. The remaining 3,474,900 shares are now open to the general public.
NMB Capital Limited has been appointed as the issue manager. Investors can apply for a minimum of 10 units and a maximum of 11,000 units.
According to CARE Ratings Nepal Limited, the company’s issuer rating has been upgraded from CARE-NP B- to CARE-NP B, indicating a high level of default risk.
Established in 2009, Sopan Pharmaceuticals manufactures generic and cephalosporin drugs from its Lalitpur-based facility. The company holds licenses for producing 139 types of medicines and marketing 70 different products.